Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
Abstract EGFR mutant non-small cell lung cancer patients' disease demonstrates remarkable responses to EGFR-targeted therapy, but inevitably they succumb to acquired resistance, which can be complex and difficult to treat. Analyzing acquired resistance through broad molecular testing is crucial...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-10-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-021-00231-x |